Ezetimibe Tablet
FDA Label NDC 60429-982

27 label sections · Submitted to the FDA by Golden State Medical Supply, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Golden State Medical Supply, Inc. for the product Ezetimibe (NDC 60429-982). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2 dosage and administration, 3 dosage forms and strengths, 4 contraindications, 5.1 risks associated with combination treatment with a statin, fenofibrate, or other ldl-c lowering therapies, 5.2 liver enzymes, 5.3 myopathy/rhabdomyolysis, 6 adverse reactions, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

2 Dosage And Administration

  • The recommended dose of ezetimibe tablet is 10 mg orally once daily, administered with or without food.
  • If as dose is missed, take the missed dose as soon as possible. Do not double the next dose.
  • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ezetimibe tablets.
  • Administer ezetimibe tablets at least 2 hours before or 4 hours after administration of a bile acid sequestrant [ see Drug Interactions (7)].

3 Dosage Forms And Strengths

10 mg tablets are white to off-white, capsule-shaped uncoated tablets with " E 10" debossed on one side and plain on other side.

4 Contraindications

Ezetimibe tablets are contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported [ see Adverse Reactions (6.2)].

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe tablets are contraindicated in patients for whom a statin, fenofibrate, or other LDLC lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications [see Warnings and Precautions (5.1)]

6.1 Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a

drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical

practice.

Monotherapy

In 10 double-blind, placebo-controlled clinical trials, 2,396 patients with primary hyperlipidemia (age range 9 to 86 years; 50% female, 90% White, 5% Black or African American, 2% Asian, 3% other races; 3% identified as Hispanic or Latino ethnicity) and elevated LDL-C were treated with ezetimibe tablets 10 mg daily for a median treatment duration of 12 weeks (range 0 to 39 weeks).

Adverse reactions reported in ≥ 2% of patients treated with ezetimibe tablets and at an incidence greater than placebo in placebo-controlled studies of ezetimibe tablets are shown in Table 1.

TABLE 1: Adverse Reactions Occurring in ≥ 2% and Greater than Placebo in ezetimibe tablets -treated Patients

Adverse ReactionsPlacebo (%) n=1,159

Ezetimibe tablets 10mg (%)

n=2,396

Upper respiratory tract infection2.54.3
Diarrhea3.74.1
Arthralgia2.23.0
Sinusitis2.22.8
Pain in extremity2.52.7
Fatigue1.52.4
1.52.0

Combination with a Statin

In 28 double-blind, controlled (placebo or active-controlled) clinical trials, 11,308 patients with primary hyperlipidemia (age range 10 to 93 years, 48% female, 85% White, 7% Black or African

American, 3% Asian, 5% other races; 4% identified as Hispanic or Latino ethnicity) and elevated LDL-C were treated with ezetimibe tablets 10 mg/day concurrently with or added to on-going statin therapy for a median treatment duration of 8 weeks (range 0 to 112 weeks).

The incidence of consecutive increased transaminases (≥ 3 times ULN) was higher in patients receiving ezetimibe tablets administered with statins (1.3%) than in patients treated with statins alone (0.4%).

Adverse reactions reported in ≥2% of patients treated with ezetimibe tablets + statin and at an incidence greater than statin are shown in Table 2.

TABLE 2: Adverse Reactions Occurring ≥2% in ezetimibe tablets -treated Patients Co-administered with a Statin and at an Incidence Greater than Statin

Adverse Reaction

All Statins*

(%)

n = 9,361

All Statins*

(%)

n = 9,361

Ezetimibe Tablets + All Statins*

(%)

n = 11,308

Nasopharyngitis3.33.7
Myalgia2.73.2
Upper respiratory tract infection2.82.9
Arthralgia2.42.6
Diarrhea2.22.5
Back pain2.32.4
Influenza2.12.2
Pain in extremity1.92.1
Fatigue1.62.0

*All Statins = all doses of all statins

Combination with Fenofibrate

This clinical trial involving 625 patients with mixed dyslipidemia (age range 20 to 76 years; 44% female, 79% White, 1% Black or African American, 20% other races; 11% identified as Hispanic or Latino ethnicity) treated for up to 12 weeks and 576 patients treated for up to an additional 48 weeks evaluated co-administration of ezetimibe tablets and fenofibrate. Incidence rates for clinically important elevations (≥3 X ULN, consecutive) in hepatic transaminase levels were 4.5% and 2.7% for fenofibrate monotherapy (n=188) and ezetimibe tablets co-administered with fenofibrate (n=183), respectively, adjusted for treatment exposure. Corresponding incidence rates for cholecystectomy were 0.6% and 1.7% for fenofibrate monotherapy and ezetimibe tablets co-administered with fenofibrate, respectively [see Drug Interactions (7)].

7 Drug Interactions

Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with ezetimibe and instructions for preventing or managing them.

Table 3 Clinically Important Drug Interactions with Ezetimibe Tablets
Cyclosporine
Clinical ImpactConcomitant use of ezetimibe tablets and cyclosporine increases ezetimibe and cyclosporine concentrations. The degree of increase in ezetimibe exposure may be greater in patients with severe renal insufficiency [see Clinical Pharmacology ( 12.3)] .
InterventionMonitor cyclosporine concentrations in patients receiving ezetimibe tablets and cyclosporine. In patients treated with cyclosporine, weigh the potential effects of the increased exposure to ezetimibe from concomitant use against the benefits of alterations in lipid levels provided by ezetimibe tablets.
Fibrates
Clinical ImpactBoth fenofibrate and ezetimibe may increase cholesterol excretion into the bile, leading to cholelithiasis. Co-administration of ezetimibe tablets with fibrates other than fenofibrate is not recommended [see Adverse Reactions ( 6.1)] .
InterventionIf cholelithiasis is suspected in a patient receiving ezetimibe tablets and fenofibrate, gallbladder studies are indicated, and alternative lipid-lowering therapy should be considered.
Bile Acid Sequestrants
Clinical ImpactConcomitant cholestyramine administration decreased the mean exposure of total ezetimibe. This may result in a reduction of efficacy [see Clinical Pharmacology ( 12.3)] .
InterventionIn patients taking a bile acid sequestrant, administer ezetimibe tablets at least 2 hours before or 4 hours after the bile acid sequestrant [see Dosage and Administration ( 2)] .

10 Overdosage

In the event of overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.

11 Description

Ezetimibe is a dietary cholesterol absorption inhibitor. The chemical name of ezetimibe is 1-(4- fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C24H21F2NO3. Its molecular weight is 409.42 and its structural formula is:

Structure (Ezetimibe 1)

Structure (Ezetimibe 1)

Ezetimibe is a white to off white, crystalline powder that is freely soluble in methanol, and acetone, soluble in ethanol, and practically insoluble in water. Ezetimibe has a melting point of about 165.13°C and is stable at ambient temperature. Ezetimibe is available as a tablet for oral administration containing 10 mg of ezetimibe and the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone, pregelatinized starch (maize) and sodium lauryl sulfate.

16 How Supplied/Storage And Handling

Ezetimibe tablets, USP, 10 mg, are white to off-white, capsule-shaped uncoated tablets with “ E 10” debossed on one side and plain on other side. They are supplied as follows:

NDC60429-982-30 Bottles of 30

NDC60429-982-90 Bottles of 90

NDC60429-982-05 Bottles of 500

Storage

Store at 20° - 25° C (68° - 77° F) [See USP Controlled Room Temperature]. Protect from moisture.

17 Patient Counseling Information

Advise the patient to read the FDA-Approved Patient Labeling (Patient Information).

Inform patients that ezetimibe tablets may cause liver enzyme elevations [see Warnings and Precautions (5.2)].

Muscle Pain

Advise patients that ezetimibe tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [see Warnings and Precautions (5.3), andDrug Interactions (7)].

Pregnancy

Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if ezetimibe tablets should be discontinued [see Use in Specific Populations (8.1)].

Breastfeeding

Advise patients who have a lipid disorder and are breastfeeding to discuss the options with their healthcare provider [see Use in Specific Populations(8.2)].

Missed Dose

Instruct patients to take ezetimibe tablets only as prescribed. If a dose is missed, it should be taken as soon as possible. Advise patients not to double their next dose.

Manufactured by:

Ohm Laboratories Inc.

New Brunswick, NJ 08901

Distributed by:

Sun Pharmaceuticals Industries, Inc.

Cranbury, NJ 08512

March 2024 FDA-07

5249048

Marketed by:

GSMS, Inc.

Camarillo, CA 93012 USA

Patient Information

EZETIMIBE TABLETS, USP
(e-zet’-i-mibe)

Rx only

Read this information carefully before you start taking ezetimibe tablets, USP and each time you get more ezetimibe tablets, USP. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about ezetimibe tablets, USP, ask your doctor. Only your doctor can determine if ezetimibe tablets, USP are right for you.

What are ezetimibe tablets, USP?

Ezetimibe tablets, USP are used with a cholesterol lowering diet:

  • and with other cholesterol medicines called a statin, or alone (when additional cholesterol lowering treatments are not possible), to lower elevated low-density lipoprotein cholesterol (LDL-C) or bad cholesterol in adults with primary hyperlipidemia (too many fats in your blood), including heterozygous familial hypercholesterolemia (HeFH). HeFH is an inherited condition that causes high levels of bad cholesterol.
  • and with a statin to lower LDL-C in adults and children 10 years of age and older with HeFH.
  • and with a medicine called fenofibrate to lower elevated LDL-C in adults with mixed hyperlipidemia.
  • to lower elevated sitosterol and campesterol levels in adults and in children 9 years of age and older with homozygous familial sitosterolemia (a rare inherited condition that prevents the body from getting rid of cholesterol from plants).

    Ezetimibe tablets is also used:

    • with a statin and other cholesterol lowering treatments to lower elevated LDL-C levels in adults and patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). HoFH is an inherited condition that causes high levels of bad cholesterol.
    • The safety and effectiveness of ezetimibe tablets has not been established in children:

      • younger than 10 years of age with HeFH or HoFH.
      • younger than 9 years of age with homozygous familial sitosterolemia.
      • with other types of hyperlipemia.
      • Do not take ezetimibe tablets:

        • if you are allergic to ezetimibe or any of the ingredients in ezetimibe tablets. See the end of this Patient Information leaflet for a complete list of ingredients in ezetimibe tablets. Stop using ezetimibe tablets and get medical help right away if you have symptoms of a serious allergic reaction including:
        • o swelling of the face, tongue, or throat

          o difficulty breathing or swallowing

          o fainting or feeling dizzy o very fast heartbeat

          o severe skin rash, hives, and itching

          o flu-like symptoms including fever, sore throat, cough, tiredness, and joint pain

          • with certain statins, fenofibrate, or other LDL-C lowering medicines if your healthcare provider has told you not to take them.
          • Before you take ezetimibe tablets, tell your healthcare provider about all your medical conditions, including if you:​

            • have liver problems. Ezetimibe tablets may not be right for you.
            • are pregnant or plan to become pregnant. It is not known if ezetimibe tablets will harm your unborn baby. You and your healthcare provider should decide if you will take ezetimibe tablets while you are pregnant.
            • are breastfeeding. It is not known if ezetimibe tablets passes into your breast milk. You and your healthcare provider should decide the best way to feed your baby if you take ezetimibe tablets.
            • Tell your healthcare provider about all the medicines you take,including prescription and over-the-­counter medicines, vitamins, and herbal supplements. Talk to your healthcare provider before you start taking any new medicines. Taking ezetimibe tablets with certain other medicines may affect each other causing side effects. Ezetimibe tablets may affect the way other medicines work, and other medicines may affect how ezetimibe tablets works.

              Especially tell your healthcare provider if you take:

              • cyclosporine (a medicine for your immune system)
              • fibrates (medicine for lowering cholesterol)
              • bile acid sequestrants (medicine for lowering LDL-C)
              • Ask your healthcare provider or pharmacist for a list of medicines if you are not sure. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

                How should I take ezetimibe tablets?

                • Take ezetimibe tablets 1-time each day, with or without food. It may be easier to remember to take your dose if you do it at the same time every day, such as with breakfast, dinner, or at bedtime. If you also take another medicine to reduce your cholesterol, ask your healthcare provider if you can take them at the same time.
                • If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. Do not take 2 doses of ezetimibe tablets at the same time.
                • While taking ezetimibe tablets, continue to follow your cholesterol-lowering diet and to exercise as your healthcare provider told you to.
                • If you take a medicine called a bile acid sequestrant, take ezetimibe tablets at least 2 hours before or 4 hours after you take the bile acid sequestrant.
                • Your healthcare provider may do blood tests to check your LDL-C levels as early as 4 weeks after starting treatment with ezetimibe tablets.
                • In case of an overdose, get medical help or contact a live Poison Center expert right away at 1­-800-222-1222. Advice is also available online at poisonhelp.org.
                • What are the possible side effects of ezetimibe tablets?

                  Ezetimibe tablets may cause serious side effects including:

                  • increased liver enzymes.An increase in liver enzymes can happen in people taking ezetimibe tablets alone or with statins. Your healthcare provider may do blood tests to check your liver before and during treatment. Your healthcare provider may need to change or stop your treatment with ezetimibe tablets because of an increase in liver enzymes.
                  • muscle pain, tenderness, and weakness (myopathy). Muscle problems, including muscle breakdown (rhabdomyolysis) can happen. Tell your healthcare provider right away if:
                  • you have unexplained muscle pain, tenderness, weakness, feel more tired than usual, or fever.
                  • you have muscle problems that do not go away even after your healthcare provider has advised you to stop taking ezetimibe tablets. Your healthcare provider may do further tests to diagnose the cause of your muscle problems.
                  • Your chances of getting muscle problems are higher if you are also taking statins or fibrates.

                    The most common side effects of ezetimibe tablets taken alone include:

                    • upper respiratory
                    • joint pain
                    • pain in arms or
                    • flu-like tract infection legs symptoms
                    • diarrhea
                    • inflammation of the
                    • feeling tired sinuses
                    • The most common side effects of ezetimibe tablets taken with a statin include:

                      • runny nose, sore throat
                      • joint pain
                      • flu-like symptoms
                      • muscle aches and pains
                      • diarrhea
                      • pain in arms or legs
                      • upper respiratory tract infection
                      • back pain
                      • feeling tired
                      • Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of ezetimibe tablets.

                        Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-­FDA-1088.

                        How should I store ezetimibe tablets?

                        • Store ezetimibe tablets at room temperature between 68°F to 77°F (20°C to 25°C).
                        • Protect from moisture. Keep ezetimibe tablets and all medicines out of the reach of children.
                        • General information about safe and effective use of ezetimibe tablets.Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ezetimibe tablets for a condition for which it was not prescribed. Do not give ezetimibe tablets to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ezetimibe tablets that is written for health professionals.

                          What are the ingredients in Ezetimibe tablets?

                          Active ingredient:ezetimibe.

                          Inactive ingredients:Croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone, pregelatinized starch (maize) and sodium lauryl sulfate.

                          Manufactured by:

                          Ohm Laboratories Inc.

                          New Brunswick, NJ 08901

                          Distributed by:

                          Sun Pharmaceuticals Industries, Inc.

                          Cranbury, NJ 08512

                          March 2024 FDA-07

                          Marketed by:

                          GSMS, Inc.

                          Camarillo, CA 93012 USA

Package/Label Display Panel

60429-982-30.jpg (60429 982 30)

60429-982-30.jpg (60429 982 30)

* Please review the disclaimer below.